Cargando…

BRAF突变晚期NSCLC的靶向和免疫治疗研究进展

With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without dr...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560979/
https://www.ncbi.nlm.nih.gov/pubmed/34696543
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29
_version_ 1784593036126191616
collection PubMed
description With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without driver gene mutation, which is far from meeting the clinical needs. In recent years, targeted therapy for NSCLC patients with BRAF V600E mutations has shown good efficacy when we are still exploring the better targeted therapies for other BRAF-mutated subtypes. Immunotherapy also showed positive antitumor activity in V600E and non-V600E subtypes of BRAF-mutated NSCLC. This article reviewed the progress of immunological and targeted therapy for patients with BRAF-mutated NSCLC.
format Online
Article
Text
id pubmed-8560979
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-85609792021-11-10 BRAF突变晚期NSCLC的靶向和免疫治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without driver gene mutation, which is far from meeting the clinical needs. In recent years, targeted therapy for NSCLC patients with BRAF V600E mutations has shown good efficacy when we are still exploring the better targeted therapies for other BRAF-mutated subtypes. Immunotherapy also showed positive antitumor activity in V600E and non-V600E subtypes of BRAF-mutated NSCLC. This article reviewed the progress of immunological and targeted therapy for patients with BRAF-mutated NSCLC. 中国肺癌杂志编辑部 2021-10-20 /pmc/articles/PMC8560979/ /pubmed/34696543 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
title BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
title_full BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
title_fullStr BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
title_full_unstemmed BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
title_short BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
title_sort braf突变晚期nsclc的靶向和免疫治疗研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560979/
https://www.ncbi.nlm.nih.gov/pubmed/34696543
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29
work_keys_str_mv AT braftūbiànwǎnqīnsclcdebǎxiànghémiǎnyìzhìliáoyánjiūjìnzhǎn
AT braftūbiànwǎnqīnsclcdebǎxiànghémiǎnyìzhìliáoyánjiūjìnzhǎn
AT braftūbiànwǎnqīnsclcdebǎxiànghémiǎnyìzhìliáoyánjiūjìnzhǎn